- Home
- KTB vs MRUS Comparison
KTB vs MRUS Comparison
Compare KTB & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTB
- MRUS
- Stock Information
- Founded
- KTB 2018
- MRUS 2003
- Country
- KTB United States
- MRUS Netherlands
- Employees
- KTB N/A
- MRUS N/A
- Industry
- KTB Apparel
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- KTB Consumer Discretionary
- MRUS Health Care
- Exchange
- KTB Nasdaq
- MRUS Nasdaq
- Market Cap
- KTB 4.3B
- MRUS 3.6B
- IPO Year
- KTB N/A
- MRUS 2016
- Fundamental
- Price
- KTB $90.17
- MRUS $46.58
- Analyst Decision
- KTB Buy
- MRUS Strong Buy
- Analyst Count
- KTB 8
- MRUS 10
- Target Price
- KTB $90.71
- MRUS $86.70
- AVG Volume (30 Days)
- KTB 514.7K
- MRUS 376.4K
- Earning Date
- KTB 10-31-2024
- MRUS 10-31-2024
- Dividend Yield
- KTB 2.31%
- MRUS N/A
- EPS Growth
- KTB 17.87
- MRUS N/A
- EPS
- KTB 4.43
- MRUS N/A
- Revenue
- KTB $2,578,094,000.00
- MRUS $35,932,000.00
- Revenue This Year
- KTB $0.86
- MRUS N/A
- Revenue Next Year
- KTB $3.61
- MRUS $52.49
- P/E Ratio
- KTB $20.34
- MRUS N/A
- Revenue Growth
- KTB N/A
- MRUS N/A
- 52 Week Low
- KTB $51.76
- MRUS $22.26
- 52 Week High
- KTB $92.48
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- KTB 67.21
- MRUS 32.37
- Support Level
- KTB $89.67
- MRUS $48.42
- Resistance Level
- KTB $91.93
- MRUS $53.49
- Average True Range (ATR)
- KTB 2.81
- MRUS 2.17
- MACD
- KTB 0.67
- MRUS -0.54
- Stochastic Oscillator
- KTB 85.71
- MRUS 5.73
About KTB Kontoor Brands Inc.
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.